Omarigliptin
Omarigliptin[edit]
Omarigliptin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones in the body. These hormones help to regulate blood glucose levels by increasing insulin release and decreasing glucagon levels.
Mechanism of Action[edit]
Omarigliptin functions by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the degradation of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By inhibiting DPP-4, omarigliptin prolongs the action of these hormones, thereby enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner.
Pharmacokinetics[edit]
Omarigliptin is administered orally and is known for its once-weekly dosing schedule, which is a result of its long half-life. This makes it a convenient option for patients who may have difficulty adhering to daily medication regimens. The drug is absorbed in the gastrointestinal tract and is metabolized primarily in the liver.
Clinical Use[edit]
Omarigliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin to achieve better glycemic control. It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Side Effects[edit]
Common side effects of omarigliptin include nasopharyngitis, headache, and upper respiratory tract infection. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis and hypersensitivity reactions. Patients should be monitored for signs and symptoms of these conditions.
Contraindications[edit]
Omarigliptin is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with a history of pancreatitis.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
